Achillion HCV Candidate Shows Promising Phase I Results In Once-Daily Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech says that latest data on its protease inhibitor ACH-1625 enhances its position in negotiating partnerships for the compound.
You may also be interested in...
Deals Of The Week: Merck KGaA/Symphogen, Valeant/Medicis, Medivir/Novadex
Achillion brought in nearly $42 million in its third large fundraising over the past 24 months, but the virology-focused biotech may become an increasingly sought acquisition target as other hepatitis C candidates face hurdles or are shelved entirely.
Achillion Aiming For Best-In-Class Protease Inhibitor, Working On Home-Grown Hep C Cocktail
While hepatitis C drug developers ponder the safety and tolerability issues likely to arise when direct-acting antivirals are combined in cocktails against the virus, Achillion Pharmaceuticals, Inc., a small company in New Haven, CT, is working on a portfolio of candidates it says not only combine safely, they work better in combination.
Achillion Aiming For Best-In-Class Protease Inhibitor, Working On Home-Grown Hep C Cocktail
While hepatitis C drug developers ponder the safety and tolerability issues likely to arise when direct-acting antivirals are combined in cocktails against the virus, Achillion Pharmaceuticals, Inc., a small company in New Haven, CT, is working on a portfolio of candidates it says not only combine safely, they work better in combination.